The impact of methotrexate therapy with vitamin D supplementation on the cardiovascular risk factors among patients with psoriasis; a prospective randomized comparative study

References

• Manolis AA, Manolis TA, Melita H, et al. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019;38(1):33–54.
   PubMed Web of Science ®Google Scholar
• Liu B, Schwartz RA. Cardio-protective effects of psoriasis medications. Acta Dermatovenerol Croat. 2018;26(3):249–254.
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Chiba T, et al. Cardiovascular and metabolic diseases comorbid with psoriasis: beyond the skin. Intern Med. 2017;56(13):1613–1619.
   PubMed Web of Science ®Google Scholar
• Shah K, Mellars L, Changolkar A, et al. Real-world burden of comorbidities in US patients with psoriasis. J Am Acad Dermatol. 2017;77(2):287–292.e4.
   PubMed Web of Science ®Google Scholar
• De Vecchis R, Baldi C, Palmisani L. Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data. Anatol J Cardiol. 2016;16:2–9.
   PubMed Web of Science ®Google Scholar
• Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370.
   PubMed Web of Science ®Google Scholar
• Fu LW, Vender R. Systemic role for vitamin d in the treatment of psoriasis and metabolic syndrome. Dermatol Res Pract. 2011;2011(276079):1–4.
   Google Scholar
• Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861–867.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10.
   PubMed Web of Science ®Google Scholar
• Heinrich J, Schulte H, Schönfeld R, et al. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemost. 1995;73(03):374–379.
   PubMed Web of Science ®Google Scholar
• Heijboer AC, Blankenstein MA, Kema IP, et al. Accuracy of 6 routine 25-hydroxyvitamin D assays: influence of vitamin D binding protein concentration. Clin Chem. 2012;58(3):543–548.
   PubMed Web of Science ®Google Scholar
• Chan YH. Biostatistics 102: quantitative data – parametric & non-parametric tests. Singapore Med J. 2003;44(8):391–396.
   PubMedGoogle Scholar
• Chan YH. Biostatistics 103: qualitative data –tests of independence. Singapore Med J. 2003;44(10):498–503.
   PubMedGoogle Scholar
• Chan YH. Biostatistics 104: correlational analysis. Singapore Med J. 2003;44(12):614–619.
   PubMedGoogle Scholar
• Chandrashekar L, Kumarit GR, Rajappa M, et al. 25-hydroxy vitamin D and ischaemia-modified albumin levels in psoriasis and their association with disease severity. Br J Biomed Sci. 2015;72(2):56–60.
   PubMed Web of Science ®Google Scholar
• Bălănescu AR, Bojincă VC, Bojincă M, et al. Cardiovascular effects of methotrexate in immune-mediated inflammatory diseases. Exp Ther Med. 2019;17(2):1024–1029.
   PubMed Web of Science ®Google Scholar
• Deyab G, Hokstad I, Whist JE, et al. Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis. Arthritis Res Ther. 2017;19(1):232.
   PubMed Web of Science ®Google Scholar
• WHO CVD Risk Chart Working Group. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Health. 2019;7(10):e1332–e1345.
   PubMed Web of Science ®Google Scholar
• Mangoni AA, Zinellu A, Sotgia S, et al. Methotrexate and cardiovascular protection: current evidence and future directions. Clin Med Insights Ther. 2017;9 https://doi.org/10.1177/1179559X17741289
   Google Scholar
• Dehpouri T, Rokni GR, Narenjbon NA, et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: a pilot study. Dermatol Rep. 2019;11(1):7965. Published 2019 May 9.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 2013;27(1):e30–e41.
   PubMed Web of Science ®Google Scholar
• Owczarczyk-Saczonek A, Drozdowski M, Maciejewska-Radomska A, et al. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report. Postepy Dermatol Alergol. 2018;35(1):53–59.
   PubMed Web of Science ®Google Scholar
• Kim MR, Jeong SJ. Relationship between vitamin D level and lipid profile in non-obese children. Metabolites. 2019;9(7):125.
   Web of Science ®Google Scholar
• Rho YH, Oeser A, Chung CP, et al. Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf. 2009;2(2):34–40.
   PubMedGoogle Scholar
• Woodman RJ, Baghdadi LR, Shanahan ME, et al. The temporal relationship between arterial stiffening and blood pressure is modified by methotrexate treatment in patients with rheumatoid arthritis. Front Physiol. 2017;8:593.
   PubMed Web of Science ®Google Scholar
• Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA. 2012;308(8):788–795.
   PubMed Web of Science ®Google Scholar
• Fonseca FA, Izar MC. High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics (Sao Paulo). 2016;71(4):235–242.
   PubMed Web of Science ®Google Scholar
• Grechin C, Gheucă Solovăstru L, Vâță D, et al. Inflammatory marker alteration in response to systemic therapies in psoriasis. Exp Ther Med. 2020;20(1):42–46.
   PubMed Web of Science ®Google Scholar
• Pandey A, Goyal M. Methotrexate: CIRTified for preventing atherosclerotic events? J R Coll Physicians Edinb. 2019;49(2):136–138.
   PubMed Web of Science ®Google Scholar
• Atis O, Keles M, Cankaya E, et al. Vitamin D treatment effect on serum endocan and high-sensitivity C-reactive protein levels in renal transplant patients. Prog Transpl. 2016;26(4):335–339.
   PubMed Web of Science ®Google Scholar
• Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I, et al. Studying the effect of systemic and biological drugs on intima-media thickness in patients suffering from moderate and severe psoriasis. J Eur Acad Dermatol Venereol. 2018;32(9):1492–1498.
   PubMed Web of Science ®Google Scholar
• Kisiel B, Kruszewski R, Juszkiewicz A, et al. Methotrexate, cyclosporine A, and biologics protect against atherosclerosis in rheumatoid arthritis. J Immunol Res. 2015;2015:759610.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim MJ, Lee CK, et al. Effects of methotrexate on carotid intima media thickness in patients with rheumatoid arthritis. J Korean Med Sci. 2015;30(11):1589–1596.
   PubMed Web of Science ®Google Scholar
• Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106–2111.
   PubMed Web of Science ®Google Scholar
• Tanaka F, Komi R, Makita S, et al. Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens. 2016;34(3):506–512.
   PubMed Web of Science ®Google Scholar
• Olsen MH, Sehestedt T, Lyngbaek S, et al. Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide-three new cardiovascular risk markers-do they improve risk prediction and influence treatment? Curr Vasc Pharmacol. 2010;8(1):134–139.
   PubMed Web of Science ®Google Scholar
• Liyanage P, Lekamwasam S, Weerarathna TP, et al. Effect of vitamin D therapy on urinary albumin excretion, renal functions, and plasma renin among patients with diabetic nephropathy: a randomized, double-blind clinical trial. J Postgrad Med. 2018;64(1):10–15.
   PubMed Web of Science ®Google Scholar
• Svendsen KB, Ellingsen T, Bech JN, et al. Urinary excretion of alpha-GST and albumin in rheumatoid arthritis patients treated with methotrexate or other DMARDs alone or in combination with NSAIDs. Scand J Rheumatol. 2005;34(1):34–39.
   PubMed Web of Science ®Google Scholar
• Yang SL, Zhao FY, Song H, et al. Methotrexate associated renal impairment is related to delayed elimination of high-dose methotrexate. ScientificWorldJournal. 2015;2015:1–8.
   Google Scholar
• El-Komy MHM, Mashaly H, Sayed KS, et al. Clinical and epidemiologic features of psoriasis patients in an Egyptian medical center. JAAD Int. 2020;1(2):81–90.
   PubMedGoogle Scholar
• Earthman CP, Beckman LM, Masodkar K, et al. The link between obesity and low circulating 25-hydroxyvitamin D concentrations: considerations and implications. Int J Obes (Lond). 2012;36(3):387–396.
   PubMed Web of Science ®Google Scholar
• Barrea L, Savanelli MC, Di Somma C, et al. Vitamin D and its role in psoriasis: an overview of the dermatologist and nutritionist. Rev Endocr Metab Disord. 2017;18(2):195–205.
   PubMed Web of Science ®Google Scholar
• El-Moaty Zaher HA, El-Komy MHM, Hegazy RA, et al. Assessment of interleukin-17 and vitamin D serum levels in psoriatic patients. J Am Acad Dermatol. 2013;69(5):840–842.
   PubMed Web of Science ®Google Scholar
• McConnell JP, Foley KF, Vargas GM. Hypovitaminosis D: a new risk marker for cardiovascular disease. Clin Lab Sci. 2009;22(4):240–246.
   PubMedGoogle Scholar
• Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008;117(4):503–511.
   PubMed Web of Science ®Google Scholar
• Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens. 2007;20(7):713–719.
   PubMed Web of Science ®Google Scholar
• Barbarawi M, Kheiri B, Zayed Y, et al. Vitamin D supplementation and cardiovascular disease risks in more than 83 000 individuals in 21 randomized clinical trials: a meta-analysis. JAMA Cardiol. 2019;4(8):765–776.
   PubMed Web of Science ®Google Scholar